Michael Durkin

432 total citations
25 papers, 327 citations indexed

About

Michael Durkin is a scholar working on Psychiatry and Mental health, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Michael Durkin has authored 25 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Psychiatry and Mental health, 6 papers in Surgery and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Michael Durkin's work include Mental Health Treatment and Access (4 papers), Diabetes Treatment and Management (4 papers) and Schizophrenia research and treatment (4 papers). Michael Durkin is often cited by papers focused on Mental Health Treatment and Access (4 papers), Diabetes Treatment and Management (4 papers) and Schizophrenia research and treatment (4 papers). Michael Durkin collaborates with scholars based in United States, United Kingdom and Canada. Michael Durkin's co-authors include Steven C. Marcus, Zena Stein, Philip J. Belmont, Luella Engelhart, Arthur K. Melkonian, Greg Maislin, Nathan L. Kleinman, G. Viale, Dominick Latrémouille-Viau and Jacques LeLorier and has published in prestigious journals such as Neurology, Diabetes and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

Michael Durkin

24 papers receiving 300 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Durkin United States 10 197 94 83 68 28 25 327
M Ojanen Finland 7 54 0.3× 18 0.2× 55 0.7× 93 1.4× 57 2.0× 8 373
Katie E. J. Hann United Kingdom 6 86 0.4× 15 0.2× 56 0.7× 178 2.6× 30 1.1× 6 539
Dee Lin United States 10 184 0.9× 35 0.4× 24 0.3× 44 0.6× 53 1.9× 45 284
Helen Millar United Kingdom 11 235 1.2× 29 0.3× 17 0.2× 57 0.8× 40 1.4× 22 370
Alison Littlewood United Kingdom 7 225 1.1× 18 0.2× 18 0.2× 79 1.2× 32 1.1× 8 389
Donna Spencer United States 8 112 0.6× 43 0.5× 41 0.5× 63 0.9× 8 0.3× 19 296
Sean Lynch United Kingdom 8 89 0.5× 6 0.1× 54 0.7× 43 0.6× 11 0.4× 22 322
Warachal Faison United States 8 102 0.5× 59 0.6× 8 0.1× 29 0.4× 22 0.8× 16 290
Adrienne Y L Chan Hong Kong 10 65 0.3× 48 0.5× 78 0.9× 23 0.3× 6 0.2× 17 336
Catherine Fox United States 6 69 0.4× 32 0.3× 221 2.7× 53 0.8× 4 0.1× 11 445

Countries citing papers authored by Michael Durkin

Since Specialization
Citations

This map shows the geographic impact of Michael Durkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Durkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Durkin more than expected).

Fields of papers citing papers by Michael Durkin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Durkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Durkin. The network helps show where Michael Durkin may publish in the future.

Co-authorship network of co-authors of Michael Durkin

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Durkin. A scholar is included among the top collaborators of Michael Durkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Durkin. Michael Durkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Qiao, Edmund M., Vinit Nalawade, Nikhil V. Kotha, et al.. (2021). Evaluating the clinical trends and benefits of low‐dose computed tomography in lung cancer patients. Cancer Medicine. 10(20). 7289–7297. 6 indexed citations
3.
4.
5.
6.
7.
Blonde, Lawrence, Joseph A. Vassalotti, Dominic Pilon, et al.. (2019). 14-OR: The Cost of Chronic Kidney Disease Progression in Type 2 Diabetes Patients. Diabetes. 68(Supplement_1). 1 indexed citations
8.
9.
Wells, Philip S., Anthonie W.A. Lensing, Lloyd Haskell, et al.. (2018). Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results. Journal of Medical Economics. 21(6). 587–594. 2 indexed citations
10.
11.
Goodman, Michael J., et al.. (2012). Assessing adherence-based quality measures in epilepsy. International Journal for Quality in Health Care. 24(3). 293–300. 13 indexed citations
12.
Marcus, Steven C. & Michael Durkin. (2011). Stimulant Adherence and Academic Performance in Urban Youth With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 50(5). 480–489. 44 indexed citations
13.
Kleinman, Nathan L., et al.. (2009). Incremental Employee Health Benefit Costs, Absence Days, and Turnover Among Employees With ADHD and Among Employees With Children With ADHD. Journal of Occupational and Environmental Medicine. 51(11). 1247–1255. 31 indexed citations
14.
Duh, Mei Sheng, Pierre Emmanuel Paradis, Dominick Latrémouille-Viau, et al.. (2009). The risks and costs of multiple-generic substitution of topiramate. Neurology. 72(24). 2122–2129. 61 indexed citations
15.
Gianfrancesco, Frank D., Michael Durkin, Ramy Mahmoud, & Ruey‐Hua Wang. (2002). Use of Healthcare Services by Patients Treated with Risperidone Versus Conventional Antipsychotic Agents. PharmacoEconomics. 20(6). 413–427. 15 indexed citations
16.
17.
Fuller, Matthew A., et al.. (2002). Service Use and Costs Among VA Patients With Schizophrenia Taking Risperidone or Olanzapine. Psychiatric Services. 53(7). 855–860. 20 indexed citations
18.
Hall, J., Sheri Dodd, Michael Durkin, & Sheldon Sloan. (2002). Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.. PubMed. 11(7 Suppl). 14–8. 13 indexed citations
19.
Carter, Kate, Michael J. Stevens, & Michael Durkin. (1998). Effects of risperidone therapy on the use of mental health care resources in Salt Lake County, Utah. Clinical Therapeutics. 20(2). 352–363. 15 indexed citations
20.
Stein, Zena, Philip J. Belmont, & Michael Durkin. (1987). Mild mental retardation and severe mental retardation compared: experiences in eight less developed countries.. PubMed. 44. 89–96. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M Ojanen Breakdown of academic impact, for papers by Katie E. J. Hann Breakdown of academic impact, for papers by Dee Lin Breakdown of academic impact, for papers by Helen Millar Breakdown of academic impact, for papers by Alison Littlewood Breakdown of academic impact, for papers by Donna Spencer Breakdown of academic impact, for papers by Sean Lynch Breakdown of academic impact, for papers by Warachal Faison Breakdown of academic impact, for papers by Adrienne Y L Chan Breakdown of academic impact, for papers by Catherine Fox
Rankless by CCL
2026